{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:00Z","timestamp":1791475500709,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1053\/j.ajkd.2014.10.014","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T21:02:47Z","timestamp":1415134967000},"page":"728-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5"],"prefix":"10.1053","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct01736397","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Geoffrey A.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Shemesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2014.10.014_bib1","first-page":"e1","article-title":"Introduction to volume one: US Renal Data System 2013 annual data report","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.014_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.ki.5000105","article-title":"Association of anemia with outcomes in men with moderate and severe chronic kidney disease","volume":"69","author":"Kovesdy","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2014.10.014_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004","volume":"4","author":"Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.014_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Drueke","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1185\/03007995.2012.761599","article-title":"Tolerability of different oral iron supplements: a systematic review","volume":"29","author":"Cancelo-Hidalgo","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.05320513","article-title":"A\u00a0randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD","volume":"9","author":"Macdougall","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.014_bib7","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/ndt\/gfq808","article-title":"Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease","volume":"26","author":"O'Seaghdha","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2014.10.014_bib8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2011020175","article-title":"Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition","volume":"22","author":"Zoccali","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2014.10.014_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2215\/CJN.07810910","article-title":"Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction","volume":"6","author":"Bellasi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.014_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2013.3","article-title":"Fibroblast growth factor 23 is not associated with and does not induce arterial calcification","volume":"83","author":"Scialla","year":"2013","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2014.10.014_bib11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2215\/CJN.00810110","article-title":"Serum phosphate and mortality in patients with chronic kidney disease","volume":"5","author":"Eddington","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.014_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.014_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/archinte.167.9.879","article-title":"Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community","volume":"167","author":"Dhingra","year":"2007","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1053\/j.ajkd.2014.10.014_bib14","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MNH.0b013e32835422ad","article-title":"Klotho in health and disease","volume":"21","author":"Kuro-o","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2014.10.014_bib16","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1053\/j.ajkd.2014.10.014_bib17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.014_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.014_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.014_bib20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.ajkd.2013.01.007","article-title":"Effect of protein restriction on serum and urine phosphate in the Modification of Diet in Renal Disease (MDRD) Study","volume":"61","author":"Newsome","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2014.10.014_bib21","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study [published online ahead of print May 20, 2014]","author":"Lee","year":"2014","journal-title":"J\u00a0Nephrol"},{"key":"10.1053\/j.ajkd.2014.10.014_bib22","doi-asserted-by":"crossref","unstructured":"Lewis JB, Sika M, Koury MJ, et al; for the Collaborative Study Group. Ferric citrate controls phosphorus and delivers iron in patients on dialysis [published online ahead of print July 24, 2014]. J Am Soc Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2014020212.","DOI":"10.1681\/ASN.2014020212"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.014_bib23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A\u00a0randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib24","first-page":"261","article-title":"Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis","volume":"24","author":"Yokoyama","year":"2014","journal-title":"J\u00a0Ren Nutr"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.014_bib25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Yokoyama","year":"2012","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.014_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J\u00a0Biopharm Stat"},{"issue":"5","key":"10.1053\/j.ajkd.2014.10.014_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000096174","article-title":"A\u00a0randomized controlled trial of oral versus intravenous iron in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.014_bib28","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2014.10.014_bib29","first-page":"18","article-title":"The efficacy of a single dose of intravenous ferric carboxymaltose on anaemia in a pre-dialysis population of chronic kidney disase patients","volume":"35","author":"Tagboto","year":"2009","journal-title":"J\u00a0Ren Care"},{"issue":"6","key":"10.1053\/j.ajkd.2014.10.014_bib30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/j.ajkd.2012.10.027","article-title":"Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis","volume":"61","author":"Vaziri","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2014.10.014_bib31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2014.10.014_bib32","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2014.10.014_bib33","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2014.10.014_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"issue":"23","key":"10.1053\/j.ajkd.2014.10.014_bib35","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.ajkd.2014.10.014_bib36","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2215\/CJN.02640310","article-title":"Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis","volume":"5","author":"Gutierrez","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2014.10.014_bib37","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.014_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2013.03.042","article-title":"Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation","volume":"62","author":"Block","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2014.10.014_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2012.11.033","article-title":"Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study","volume":"61","author":"Dominguez","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2014.10.014_bib41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ki.2012.303","article-title":"Dietary phosphorus is associated with greater left ventricular mass","volume":"83","author":"Yamamoto","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2014.10.014_bib43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3945\/ajcn.113.073148","article-title":"High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III","volume":"99","author":"Chang","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1053\/j.ajkd.2014.10.014_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3945\/ajcn.112.053934","article-title":"Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population","volume":"98","author":"Calvo","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.ajkd.2014.10.014_bib45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2013.145","article-title":"No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease","volume":"84","author":"Mehrotra","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2014.10.014_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjmed.2012.08.018","article-title":"Phosphorus and risk of renal failure in subjects with normal renal function","volume":"126","author":"Sim","year":"2013","journal-title":"Am J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614013572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614013572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:29:38Z","timestamp":1759458578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614013572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0272638614013572"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.014","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}